Novidat - Ciprofloxacin TabletsNovidat contains Ciprofloxacin, a drug from the quinolone group of antibiotics.  Novidat is also known as a DNA Gyrase Inhibitor. Novidat has strong antibacterial action against a broad spectrum of bacteria. It prevents transcription by the chromosomes of the information needed for the normal metabolism of bacteria. This leads to a rapid decrease in the ability of bacteria to reproduce.

Novidat is characterized by the fact that, as a result of its particular mode of action, it does not generally exhibit parallel resistance to any other antibiotic outside the Gyrase Inhibitor group. Therefore, Novidat is highly effective against bacteria which are resistant, for example, to aminoglycosides, Penicillin, cephalosporins, tetracyclines and other antibiotics.

Novidat – Clinical Pharmacology

The absolute bioavailability of Novidat (ciprofloxacin) is 70 to 80%. The maximum blood concentration is reached just 60-90 minutes after ingestion. Novidat is present in high concentrations at the sites of infections, i.e. in the body fluids and tissues. It only needs to be taken twice daily, once in the morning and once in the evening.

Novidat (Ciprofloxacin) Indications

In the treatment of outpatients with pneumonia due to pneumococcus, Novidat should not be used as a first choice of drug.

Novidat is used to treat infections caused by pathogens which are sensitive to ciprofloxacin.

  • Novidat can be regarded as an advisable treatment for pneumonia caused by Klebsiella, Enterobacter, Proteus, Pseudomonas, Haemophilus, Branhamella, Legionella and Staphylococcus.
  • Middle ear (otitis media), of the paranasal sinuses (sinusitis), especially if these are caused by gram negative organisms including Pseudomonas or by Staphylococcus.
  • Kidneys and urinary tract infections.
  • Gonorrhoea
  • Bacterial infections of the gastro-intestinal tract, biliary tract, peritonitis
  • Skin and soft tissue infections
  • Bone and joint infections

Novidat Contraindications

Novidat should not be used where there is hypersensitivity to ciprofloxacin or to other chemotherapeutic agents of the quinolone group. Novidat should not be prescribed to children, growing adolescents and pregnant or nursing women, as there is no evidence of its safety when used in these groups and, on the basis of results from animal experiments, injury to the articular cartilage of an organism which is not fully grown, cannot be completely ruled out. Animal experiments have not shown any evidence of teratogenic effects.